Duluth, Ga., and Pittsboro, N.C. - Biolex Therapeutics, Inc and Merial Ltd today announced that they have entered into a new, broad-ranging research and development collaboration to produce innovative ...

Octoplus will provide manufacturing and process development services and stands to earn $138 million in milestones. Biolex Therapeutics is paying OctoPlus $11 million for its 50% share of commercial ...

Biolex CEO Jan Turek notes something unforeseen in the ePRO element of the company's recent trial of a hepatitis C treatment: The degree of difference in reports of side-effect severity in the weekly ...

Biolex Therapeutics, a Triangle-based biotechnology company, said Monday it has raised $60 million in new funding from private investors – an amount believed to be one of the largest rounds of venture ...

PITTSBORO, NORTH CAROLINA, November 28, 2006 - Biolex Therapeutics today announced results published in Nature Biotechnology demonstrating the ability of its proprietary LEX SystemSM to produce ...

Biolex Therapeutics has announced three new additions to its management team. Each of these pharmaceutical executives brings a proven track record in the development and commercialization of ...

Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron® will be presented today at the 44th Annual Meeting of the European ...

PITTSBORO - Weeks after withdrawing plans for an initial public offering, Biolex is eyeing what is likely to be a temporary slowdown of its ambitious plans to put three drug candidates through human ...

PITTSBORO -- Biolex Inc., which attempts to produce protein components for potential human and animal drugs from the aquatic plant duckweed, is closing in on a $20 million cash infusion. Insiders ...

With an alternative way of producing proteins from plants as a selling point, Biolex Inc. raised $24 million in its latest private round, which it hopes will be its last. "We had three previous rounds ...

Biolex Therapeutics, a Pittsboro, N.C.-based drug company whose lead candidate focuses on hepatitis C, has raised $30 million in Series C funding. Investor Growth Capital led the deal, and was joined ...